IVI has been selected by the Patient-Centered Outcomes Research Institute (PCORI) for a Eugene Washington PCORI Engagement Award. The $50,000 award will be used to convene a multi-stakeholder forum in February 2020 to review established and emerging approaches for improving value assessment and then identify and prioritize potential areas for research investment and collaborative solutions. [...]
In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. As our findings make clear, it [...]
In a new Value Blueprints research brief, IVI explores the novel concept of “Insurance Value.” New medical technologies not only benefit patients, but also healthy people at risk of future illness. The insurance value arising from the decreased physical risk from illness is a potentially important dimension to consider in value assessment, especially when decisions [...]
Thank you for your comments! IVI has released all public feedback received during the open comment period for the IVI-NSCLC model - our open-source platform to assess therapy sequences for EGFR+ non-small cell lung cancer. In the spirit of IVI's mission of collaboration, commitment to transparency, and dedication to iterative improvement, we look forward to [...]
The IVI team sat down with the Journal of Clinical Pathways while at ISPOR for an in-depth discussion about why advanced value assessment is needed and how it’s progressing. The team also discussed the QALY – what it is and whether it can be improved. To listen to the podcast or read the transcript, click [...]
IVI launches a new research brief series to present research findings and method insights from the OSVP. Let’s sparks a conversation into next-gen value assessment. Read the full press release here.
IVI released our initial version of the new Open-Source Value Platform (OSVP) model for non-small cell lung cancer. Specifically, the model provides information on the relative value of sequential treatments for epidermal growth factor receptor positive (EGFR+), non-squamous non-small cell lung cancer (NSCLC). The entirety of the IVI-NSCLC model package, including detailed methods documentation, R [...]
Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]
Los Angeles, CA – November 13, 2018 – The Innovation and Value Initiative (IVI) – a collaboration dedicated to advancing the science and improving the practice of value assessment in healthcare – will present research at this week’s ISPOR Europe 2018 conference showcasing different elements of the Open-Source Value Project (OSVP) initiative to facilitate assessment [...]
ISPOR Conference Examines How New Approaches to Value Assessment May Help Move Toward More Informed Pricing Washington, D.C. –- October 19, 2018 -- At the ISPOR Summit 2018, the lead scientific advisor for the Innovation and Value Initiative (IVI) - a collaboration dedicated to advancing the science and improving the practice of value assessment in [...]
